DIAGMASS

Technology

the bloodstream.

robotization, ...)







Keywords

- Diagnosis
- **Invasive Fungal** Infections (IFI)
- Panfungal test
- Mass Spectrometry
- Circulating **Biomarkers**



Intellectual **Property**

Priority Patent FR1201796 June 2012 Europe, US, China, and Japan are delivered



Benefits

New rapid detection method taking advantage of circulating fungal molecules using a physico-chemical method.

DIAGMASS is a diagnosis method for invasive fungal infections (IFI) based on

mass spectrometry detection (MALDI-TOF) of specific fungal metabolites in

The method was transposed in 2022 on a commercial column, making it

possible to consider miniaturization and automation (96-well plates,

A CHEST

A first Proof of Concept has been obtained with an artisanal column.

- This method makes it possible to quickly determine if the infection is of the fungal type and to set up an appropriate treatment.
- Robust, sensitive and specific test based on MALDI-TOF type mass spectrometry which has found its place in clinical microbiology for the identification of isolated germs and which is available in many hospitals.
- This Technique is independent of the brand of the equipment used (use of an internal standard).



Development Status

- Clinical POC obtained.
- Method tested and validated on different brands of MALDI-TOF
- Next steps: miniaturization, automation and testing on clinical spectroscopy.

Partnership

Licensing

Applications

health@sattnord.fr

Rapid diagnosis of invasive fungal infections in hospitals

find other technologies on



+33 3 28 36 04 68 - tech@sattnord.fr